Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Almac has announced the launch of Next Generation Sequencing service to support the development of personalized medicine.
Subscribe to our email newsletter
The service will aid in the development of molecular tests for trial enrichment and companion diagnostic development, focussing on targeted re-sequencing.
Almac Diagnostics business unit president and managing director, Queens University Belfast molecular oncology professor Paul Harkin said the NGS field has now moved to a point where it is a viable delivery platform and as such is a logical addition to the company’s suite of services.
"We have already begun the process of developing CLIA based assays for important mutations involved in drug response," Harkin added.
Almac already performs Next Generation Sequencing for Omixon, a bioinformatics company focused on the development of validated data analysis solutions to scientists working in genomics with special emphasis on clinical and diagnostic applications.
Omixon founder and chief executive officer Attila Berces said the MiSeq data the company received from Almac is of high quality which helped Omixon in developing and validating its HLA-typing software.
"Next Generation Sequencing can revolutionize HLA-typing which is carried out on millions of samples annually," Berces added.